Baltimore-based Johns Hopkins University launched a national drug supply chain dashboard in June 2025 to track production data, shortage history and vulnerability risks across more than 60,000 drugs.
The tool aggregates public data on drug manufacturing, FDA inspections and supply history to help policymakers, providers and health systems identify vulnerabilities in the pharmaceutical supply chain, according to an Oct. 6 report from Johns Hopkins.
Only 14% of active pharmaceutical ingredients used in U.S. generics are made domestically. Researchers said the dashboard can help users assess drug-level risk, track manufacturer concentration and inform contingency planning during regulatory actions or supply disruptions.
The dashboard is updated quarterly and includes information on shortage duration, sourcing locations and regulatory actions. Johns Hopkins said it aims to support resilience efforts amid a growing reliance on foreign manufacturing and ongoing drug shortages.
